These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26432857)

  • 1. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
    Ratzer R; Iversen P; Börnsen L; Dyrby TB; Romme Christensen J; Ammitzbøll C; Madsen CG; Garde E; Lyksborg M; Andersen B; Hyldstrup L; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler; 2016 Jun; 22(7):926-34. PubMed ID: 26432857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
    Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
    Börnsen L; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
    Mult Scler; 2011 Jan; 17(1):32-42. PubMed ID: 20921238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.
    van den Hombergh WMT; Kersten BE; Knaapen-Hans HKA; Thurlings RM; van der Kraan PM; van den Hoogen FHJ; Fransen J; Vonk MC
    Trials; 2018 Aug; 19(1):449. PubMed ID: 30134971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
    Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].
    Delmont E; Chanalet S; Bourg V; Soriani MH; Chatel M; Lebrun C
    Rev Neurol (Paris); 2004 Jul; 160(6-7):659-65. PubMed ID: 15247854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease.
    Hohol MJ; Olek MJ; Orav EJ; Stazzone L; Hafler DA; Khoury SJ; Dawson DM; Weiner HL
    Mult Scler; 1999 Dec; 5(6):403-9. PubMed ID: 10618696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].
    Zingler VC; Strupp M; Jahn K; Gross A; Hohlfeld R; Brandt T
    Nervenarzt; 2005 Jun; 76(6):740-7. PubMed ID: 15803287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone.
    Humm AM; Z'Graggen WJ; Bühler R; Magistris MR; Rösler KM
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):345-50. PubMed ID: 16174651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
    Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.
    Zéphir H; de Seze J; Dujardin K; Dubois G; Cabaret M; Bouillaguet S; Ferriby D; Stojkovic T; Vermersch P
    Mult Scler; 2005 Jun; 11(3):360-3. PubMed ID: 15957521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
    Chowdhury SA; Lin J; Sadiq SA
    Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
    Fox RJ; Fisher E; Tkach J; Lee JC; Cohen JA; Rudick RA
    Mult Scler; 2005 Apr; 11(2):140-5. PubMed ID: 15794385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid neopterin, but not osteopontin, is a valuable biomarker for the treatment response in patients with HTLV-I-associated myelopathy.
    Nagai M; Tsujii T; Iwaki H; Nishikawa N; Nomoto M
    Intern Med; 2013; 52(19):2203-8. PubMed ID: 24088752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.
    Walker JE; Giri SN; Margolin SB
    Mult Scler; 2005 Apr; 11(2):149-58. PubMed ID: 15794387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.